Molly Henderson
2023 - Phathom Pharmaceuticals
In 2023, Molly Henderson earned a total compensation of $1.9M as Chief Financial and Business Officer at Phathom Pharmaceuticals, a 29% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $260,888 |
|---|---|
| Option Awards | $281,105 |
| Salary | $500,000 |
| Stock Awards | $814,925 |
| Other | $16,875 |
| Total | $1,873,793 |
Henderson received $814.9K in stock awards, accounting for 43% of the total pay in 2023.
Henderson also received $260.9K in non-equity incentive plan, $281.1K in option awards, $500K in salary and $16.9K in other compensation.
Rankings
In 2023, Molly Henderson's compensation ranked 536th out of 2,311 executives tracked by ExecPay. In other words, Henderson earned more than 76.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 536 out of 2,311 | 77th |
Division Manufacturing | 298 out of 1,247 | 76th |
Major group Chemicals And Allied Products | 207 out of 705 | 71st |
Industry group Drugs | 205 out of 676 | 70th |
Industry Pharmaceutical Preparations | 131 out of 490 | 73rd |
Source: SEC filing on April 12, 2024.
Henderson's colleagues
We found two more compensation records of executives who worked with Molly Henderson at Phathom Pharmaceuticals in 2023.
News
Phathom Pharmaceuticals CEO Terrie Curran's 2023 pay falls 32% to $3.4M
April 12, 2024
Phathom Pharmaceuticals CEO Terrie Curran's 2022 pay slips 20% to $5M
April 13, 2023
UroGen Pharma Ltd. CEO Elizabeth Barrett's 2020 pay falls 90% to $2.5M
April 28, 2021
Advaxis CEO Kenneth Berlin's 2020 pay jumps 21% to $1.2M
April 21, 2021